Key Highlights
● uniQure released 48-month AMT-130 data on September 29, 2026; shares traded near $25.32 at midday after a steeper premarket drop.
● High-dose patients showed slowing on the composite scale, but it was not statistically significant and smaller than at three years.
● More than half of the external-control data was missing, and the CEO argued the bias cuts against the therapy.
● ClearPoint Neuro, whose platform delivers AMT-130 into the brain, plunged in sympathy with uniQure on the same day.
uniQure N.V. (NASDAQ:QURE) collapsed on Tuesday, September 29, 2026, after the gene therapy developer released 48-month data for AMT-130, its experimental treatment for Huntington's disease. Shares traded around $25.32 at midday, after a far steeper drop in premarket trading, making uniQure one of the worst small-cap performers on a day when the Russell 2000 finished lower.
What the Data Showed
AMT-130 is a one-time gene therapy delivered directly into the brain. In the Phase I/II study, high-dose patients showed slowing of disease progression on the composite Unified Huntington's Disease Rating Scale, or cUHDRS, compared with an external control group. But at four years, that result was not statistically significant, and the slowing was smaller than the company had reported at three years. The therapy also showed slowing on Total Functional Capacity, a measure of daily functioning. Chief Executive Matt Kapusta said the trends are positive and meaningful for patients, and the chief medical officer said the therapy continues to show meaningful slowing.
Why the Market Reacted So Sharply
Statistical significance is the benchmark regulators and investors use to judge whether a result is likely real rather than chance. Missing it on a primary measure raises questions about how strong the evidence is. The FDA had said 36-month data would underpin the company's Biologics license application, so weaker four-year data can complicate the story even if the three-year results remain the basis for the filing.
The Comparison Group Debate
More than half of the external-control data was missing. Kapusta argued that this cut against the therapy rather than in its favor, saying the comparator increasingly reflected a healthier population than at baseline.
Spillover and a Soft Market
ClearPoint Neuro, whose platform is used to deliver AMT-130 into the brain, plunged in sympathy. Health care was among the declining sectors at midday. The 30-year Treasury Yield reached its highest level since 2002, and the 10-year touched its highest in roughly two decades. The S&P 500 slipped 12.85 points, or 0.17%, to 7,670.84, while the Dow Jones Industrial Average fell 131.59 points to 51,349.92 and the Nasdaq Composite finished nearly flat at 26,797.54.
The Unmet Need
Huntington's disease is an inherited, fatal brain disorder that causes movement, cognitive and psychiatric symptoms, and it has no approved treatment that slows its progression. That unmet need explains both the high hopes for AMT-130 and the sharp reaction to weaker data.
Decision Points
The key question is how regulators weigh the four-year results alongside the 36-month data. Any update on FDA interactions or filing timeline will be closely watched. GDP and August PCE Inflation arrive on Wednesday, September 30, Nike reports on Thursday, October 1, and the September jobs report follows on Friday, October 2.






Please wait processing your request...